RIGL
Rigel Pharmaceuticals Inc
48.20$
+0.6%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +27.2% | -17.5% | +24.7% | +50.1% | +4.1% | -7.4% | +90.7% | -31.7% | +0.5% | -15.7% | +33.8% | – | |
| – | +198.9% | -46.6% | +38.6% | +185.9% | -27.9% | -23.8% | +2.2% | +5.5% | +25.3% | -22.7% | +85.1% | – | |
| – | +19.1% | -14.0% | +23.7% | +38.9% | +9.6% | -5.6% | +98.6% | -33.4% | -1.3% | -15.1% | +29.5% | – | |
| – | -50.8% | +89.1% | -8.1% | +11.6% | -8.9% | +49.8% | -19.1% | +7.8% | +45.3% | +9.3% | +19.6% | – | |
| – | +5.8% | +8.1% | -1.4% | -3.6% | +9.2% | -6.1% | +5.6% | -1.1% | +3.6% | +2.2% | +6.5% | – | |
| – | -4.1% | +14.8% | -2.6% | -1.1% | +5.8% | +2.8% | -0.2% | +0.6% | +12.1% | +4.1% | +10.1% | – | |
| – | – | -454.3% | – | +3,044.5% | +18.5% | -23.3% | +378.4% | -53.5% | -18.5% | -48.7% | +98.4% | – | |
| – | +0.4% | -1.7% | +8.3% | +1.5% | -5.1% | -5.2% | +1.1% | +1.1% | -10.3% | -15.7% | -45.6% | – | |
| – | – | -1,219.0% | – | – | +22.6% | -24.4% | +421.1% | -54.0% | -17.8% | -48.7% | +102.3% | – | |
| – | +0.9% | -47.4% | – | – | – | -92.6% | +467.7% | -175.9% | – | – | +109.6% | – | |
| – | – | -1,219.0% | – | – | +15.5% | -20.2% | +420.8% | -53.2% | +860.8% | -96.8% | +99.8% | – | |
| – | – | -303.4% | – | +836.2% | +17.8% | -21.4% | +347.2% | -51.8% | -16.9% | -45.3% | +84.2% | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.